NCT06778603View on ClinicalTrials.gov

B7-H3 NIR Imaging for Osteosarcoma Surgery

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

December 31, 2026

Conditions
OsteosarcomaResection MarginsB7-H3 ProbeLocal Recurrence
Interventions
DRUG

a targeted probe B7H3-IRDye800CW

B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.

Trial Locations (1)

100044

RECRUITING

Musculoskeletal Tumor Center, Beijing

All Listed Sponsors
collaborator

Simcere Pharmaceutical Group Limited

UNKNOWN

lead

Peking University People's Hospital

OTHER

NCT06778603 - B7-H3 NIR Imaging for Osteosarcoma Surgery | Biotech Hunter | Biotech Hunter